The CD19 antigen (95kDa) is expressed from the earliest stage of B progenitor development, on all peripheral B cells including germinal centre B cells, and all B cell lines and B cell leukaemia tested.T cell and monocytic cell lines are negative and the antigen is lost on B cell maturation to plasma cells.The antigen is a type I integral membrane glycoprotein whose in vitro inhibition will influence B cell activation and proliferation.
| Target |
CD19 |
| Reactivity |
Human |
| Host |
Mouse |
| Clonality |
Monoclonal |
| Tested Applications |
ELISA, IF/ICC, FCM |
| Recommended dilutions |
ELISA: 1/10000, IF/ICC: 1/200 - 1/1000, FCM: 1/200 - 1/400. Optimal dilutions/concentrations should be determined by the end user. |
| Immunogen |
Purified recombinant fragment of human CD19 expressed in E. coli. |
| Purification |
Unpurified Ascites. |
| Isotype |
IgG1 |
| Conjugation |
Unconjugated |
| Storage |
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Molecular Weight |
61 kDa |
| Swiss Prot |
P15391
|
| GeneID |
930
|
| Gene Symbol |
CD19 |
| OMIM |
107265
|
| HGNC |
1633 |
| Ensembl |
ENSG00000177455 |
| Buffer |
Ascitic fluid containing 0.03% sodium azide. |
| UNSPSC Code |
12352203 |
| Availability |
Shipped within 5-10 working days. |
| Note |
This product is for research use only. |